Cellares, an automated cell therapy manufacturing specialist, has signed its second agreement with an Asia-based organization in just over a week, according to Fierce Pharma. The deal is described as an automation test, continuing the company's push to bring its platform to cell therapy developers in the region.
The company has kept up a steady pace of new partnerships despite a speed bump over the summer, the report says. The source does not provide details on what that speed bump was, nor does it name the two Asian partners involved.
The back-to-back agreements suggest Cellares is actively courting Asian cell therapy developers as it works to demonstrate its automated manufacturing approach. With only one source, there are no differing accounts to compare, but the report frames the deal as part of a broader momentum for the company.